REVVITY, INC. (RVTY)

Revvity, Inc. (formerly PerkinElmer, Inc., renamed effective April 26, 2023) is a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development and diagnosis to cure, headquartered in Waltham, Massachusetts, and marketing its products and services in more than 160 countries with approximately 11,500 employees as of December 31, 2023; its common stock trades on the NYSE under "RVTY" and it is part of the S&P 500. The company operates in two reportable segments, Life Sciences and Diagnostics, and has strategically transformed its portfolio, including the March 2023 divestiture of its Applied, Food and Enterprise Services businesses for up to $2.45 billion. The Life Sciences segment provides a comprehensive suite of instruments, reagents, software and services spanning cell, gene and protein research—including radiometric detection systems, high-content screening and imaging platforms (Opera Phenix, Operetta CLS, IVIS, Quantum GX), multimode plate readers (VICTOR Nivo, EnSight, EnVision), biochemical and cell-based assay reagents (HTRF, AlphaLISA, AlphaScreen), BioLegend antibodies and immunoassay kits, gene-editing and cell-engineering tools (Pin-point, CHOSOURCE, Dharmacon reagents), informatics platforms (Signals Notebook, ChemDraw, Signals Clinical, Image Artist), and viral vector and cell/gene therapy services (Sirion Biotech)—serving global pharmaceutical, biotech and contract research organizations as well as academic institutions to accelerate drug discovery and development.

The Diagnostics segment focuses on reproductive health, immunodiagnostics, emerging market diagnostics and applied genomics, offering prenatal and newborn screening platforms (DELFIA Xpress, NeoBase, GSP kits, NeoLSD, EONIS), non-invasive prenatal testing (Vanadis NIPT), molecular and infectious disease testing tools (Chitas, PCR reagents, chemiluminescence and ELISA immunoassays), automated sample preparation and liquid handling systems (chemagic Prime, JANUS, Sciclone, HIVE CLX), umbilical cord blood banking (ViaCord), and Revvity Omics, a global multi-omic clinical testing laboratory network with sites in the U.S., Sweden, India, China and the U.K.—serving hospitals, diagnostic and clinical laboratories, and clinicians worldwide to detect genetic disorders, metabolic conditions and infectious diseases from pregnancy through early childhood and beyond.